Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ)

PURPOSE: Pazopanib has promising antiangiogenetic activity in solid cancers. The investigator-initiated phase I/II trial evaluated the combination of Topotecan with Pazopanib in platinum-resistant or intermediate-sensitive recurrent ovarian cancer (ROC). METHODS: Patients (≥ 18 years) with first or...

Descripción completa

Detalles Bibliográficos
Autores principales: Chekerov, Radoslav, Arndt, Tjadina, Pietzner, Klaus, Canzler, Ulrich, Wimberger, Pauline, Strauß, Hans-Georg, Mahner, Sven, Woelber, Linn, de Gregorio, Nikolaus, Stocker, Gertraud, von Abel, Ekkehard, Neunhoeffer, Tanja, Belau, Antje Kristina, Mustea, Alexander, Yalinkaya, Isil, Braicu, Elena Ioana, Richter, Rolf, Sehouli, Jalid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374680/
https://www.ncbi.nlm.nih.gov/pubmed/37000264
http://dx.doi.org/10.1007/s00432-023-04647-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374680/
https://www.ncbi.nlm.nih.gov/pubmed/37000264
http://dx.doi.org/10.1007/s00432-023-04647-9

Ejemplares similares